Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Pediatric Oncology

Treatment for Low and Intermediate Risk Neuroblastoma

At a Glance

For low- and intermediate-risk neuroblastoma, doctors often use a 'less is more' approach, such as watchful waiting or surgery alone. This strategy effectively cures the cancer while protecting children from long-term side effects like hearing loss or growth delays caused by intensive therapies.

When you hear the word “cancer,” your first instinct may be to prepare for a heavy, aggressive battle. However, for many children with low-risk or intermediate-risk neuroblastoma, the medical team’s primary goal is often the opposite: to treat the disease effectively while doing as little harm as possible [1].

In these cases, “doing less” is not a sign of a less-serious effort; it is a highly specialized strategy designed to ensure an excellent cure rate while protecting your child from unnecessary side effects [1][2].

Low-Risk: The Power of Observation and Surgery

Nearly half of children diagnosed with neuroblastoma fall into the low- or intermediate-risk categories [1]. For the low-risk group, the prognosis is exceptional, with survival rates often exceeding 95% [2].

  • Observation (Watchful Waiting): Some infants, particularly those with localized tumors or the unique “Stage MS,” may not need surgery or chemotherapy at all [3][4]. Doctors monitor the tumor closely with scans, waiting for it to stop growing or even disappear on its own—a process called spontaneous regression [4].
  • Surgery Alone: For many other low-risk children, a single surgery to remove the tumor is the only treatment required [2]. If the tumor is in a safe location and is MYCN non-amplified (meaning it lacks the most aggressive genetic marker), surgery alone is often the gold standard [2][5].

Intermediate-Risk: Tailored Treatment

The intermediate-risk group includes children whose tumors may be a bit more complex but still lack the high-risk genetic “fingerprints” like MYCN amplification [6][7].

The strategy here is response-based therapy [8]. This means:

  1. Limited Chemotherapy: Your child may receive a moderate course of chemotherapy (usually 4 to 8 cycles) [8].
  2. Monitoring the Response: Doctors perform scans throughout treatment. If the tumor shrinks significantly, the team may stop chemotherapy early to avoid “overtreating” the child [9][8].
  3. Surgery: Surgery is often used after the tumor has been shrunk by chemotherapy, making the procedure safer and more effective [10].

Why “Less” Can Be Better

The reason doctors work so hard to minimize treatment in these groups is to prevent late effects [1]. These are health problems that can appear years after cancer treatment ends, such as:

  • Hearing loss [11].
  • Growth or developmental delays [11].
  • Impacts on heart or kidney function [11].

By carefully stratifying patients based on their tumor’s biology, your oncology team ensures that your child receives exactly the amount of treatment they need to be cured—and no more [1][6]. This “precision medicine” approach focuses on giving your child the best possible quality of life both today and in the decades to come.

Return to the Home Page.

Common questions in this guide

What is watchful waiting for low-risk neuroblastoma?
Watchful waiting, or observation, involves closely monitoring a child's tumor with regular scans instead of immediately starting active treatment. In many low-risk cases, the tumor will stop growing or even completely disappear on its own over time.
What does it mean if my child's tumor is MYCN non-amplified?
If a tumor is MYCN non-amplified, it lacks a specific genetic marker associated with highly aggressive cancer. This generally means the tumor is considered lower risk and may be successfully treated with less intensive therapies like surgery alone.
Will my child need chemotherapy for intermediate-risk neuroblastoma?
Children with intermediate-risk neuroblastoma often receive response-based therapy, which starts with a limited course of chemotherapy. Doctors closely monitor how the tumor responds and may stop treatment early if it shrinks significantly, minimizing unnecessary exposure to the drugs.
Why do doctors recommend less aggressive treatment for lower-risk neuroblastoma?
The goal for lower-risk tumors is to cure the disease while protecting your child from 'late effects.' Late effects are long-term health problems caused by intense cancer treatments, so doctors strategically limit therapy to preserve your child's long-term quality of life.
What are the potential late effects of neuroblastoma treatment?
Late effects are health issues that can appear years after cancer treatment ends. For neuroblastoma therapies, these can include hearing loss, growth or developmental delays, and impaired heart or kidney function.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is the MYCN gene 'non-amplified' in my child's tumor?
  2. 2.If you are recommending 'observation' or 'watchful waiting,' what specific signs of tumor growth or change will you be looking for?
  3. 3.What are the chances that my child will need chemotherapy later if we start with surgery alone?
  4. 4.For intermediate-risk treatment, how many cycles of chemotherapy are planned, and how will we know if it's working?
  5. 5.What are the potential long-term side effects (late effects) of the specific chemotherapy drugs my child might receive?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Non-High-Risk Neuroblastoma: Classification and Achievements in Therapy.

    Meany HJ

    Children (Basel, Switzerland) 2019; (6(1)) doi:10.3390/children6010005.

    PMID: 30626019
  2. 2

    Long-term prognosis of low-risk neuroblastoma treated by surgery alone: an experience from a single institution of China.

    Yao W, Li K, Dong KR, et al.

    World journal of pediatrics : WJP 2019; (15(2)):148-152 doi:10.1007/s12519-018-0205-z.

    PMID: 30446974
  3. 3

    A Review of Infants With Localized Neuroblastoma That Evolve to Stage 4s Disease.

    Caroleo AM, De Bernardi B, Avanzini S, et al.

    Journal of pediatric hematology/oncology 2020; (42(6)):e483-e487 doi:10.1097/MPH.0000000000001517.

    PMID: 31135717
  4. 4

    SLIT3-mediated intratumoral crosstalk induces neuroblastoma differentiation via a spontaneous regression-like program.

    Liu M, Lv D, Yan W, et al.

    Journal of translational medicine 2025; (23(1)):598 doi:10.1186/s12967-025-06621-0.

    PMID: 40448172
  5. 5

    Results of a prospective clinical trial JN-L-10 using image-defined risk factors to inform surgical decisions for children with low-risk neuroblastoma disease: A report from the Japan Children's Cancer Group Neuroblastoma Committee.

    Iehara T, Yoneda A, Yokota I, et al.

    Pediatric blood & cancer 2019; (66(11)):e27914 doi:10.1002/pbc.27914.

    PMID: 31342649
  6. 6

    Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.

    Irwin MS, Naranjo A, Zhang FF, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(29)):3229-3241 doi:10.1200/JCO.21.00278.

    PMID: 34319759
  7. 7

    Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.

    Pinto N, Naranjo A, Ding X, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(8)):1546-1556 doi:10.1158/1078-0432.CCR-22-3032.

    PMID: 36749880
  8. 8

    Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.

    Barr EK, Naranjo A, Twist CJ, et al.

    Pediatric blood & cancer 2024; (71(8)):e31089 doi:10.1002/pbc.31089.

    PMID: 38822537
  9. 9

    Survival outcome of intermediate risk neuroblastoma at Children Cancer Hospital Egypt.

    Elzomor H, Ahmed G, Elmenawi S, et al.

    Journal of the Egyptian National Cancer Institute 2018; (30(1)):21-26 doi:10.1016/j.jnci.2018.01.001.

    PMID: 29428371
  10. 10

    A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocol.

    Iehara T, Yoneda A, Kikuta A, et al.

    BMC pediatrics 2020; (20(1)):212 doi:10.1186/s12887-020-02061-5.

    PMID: 32398048
  11. 11

    Imaging of pediatric neuroblastoma: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.

    Lai HA, Sharp SE, Bhatia A, et al.

    Pediatric blood & cancer 2023; (70 Suppl 4()):e29974 doi:10.1002/pbc.29974.

    PMID: 36184716

This page provides educational information on low- and intermediate-risk neuroblastoma treatments. It does not replace professional medical advice. Always consult your pediatric oncology team regarding your child's specific care plan.

Get notified when new evidence is published on Neuroblastoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.